Phase II Single Agent Lenalidomide (Revlimid) in Relapsed / Refratory Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2012
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2012 Celgene Corporation added as associations as reported in the European Clinical Trials Database record.
- 16 Aug 2011 New trial record